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Chronic activation of brain-derived neurotrophic fac-
tor (BDNF) receptor TrkB is a potential method to
prevent development of obesity, but the short half-
life and nonbioavailable nature of BDNF hampers
validation of the hypothesis. We report here that acti-
vation ofmuscular TrkB by the BDNFmimetic, 7,8-di-
hydroxyflavone (7,8-DHF), is sufficient to protect the
development of diet-induced obesity in female mice.
Using in vitro and in vivo models, we found that 7,8-
DHF treatment enhanced the expression of uncou-
pling protein 1 (UCP1) and AMP-activated protein
kinase (AMPK) activity in skeletal muscle, which re-
sulted in increased systemic energy expenditure,
reduced adiposity, and improved insulin sensitivity
in femalemice fed a high-fat diet. This antiobesity ac-
tivity of 7,8-DHF is muscular TrkB-dependent as 7,8-
DHF cannot mitigate diet-induced obesity in female
muscle-specific TrkB knockout mice. Hence, our
data reveal that chronic activation of muscular TrkB
is useful in alleviating obesity and its complications.
INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is a member of the
neurotrophin family, which plays an important role in synaptic
plasticity, neuronal survival, development, and differentiation
(Huang and Reichardt, 2001). Through activating its cognate re-
ceptor, the tropomyosin-related kinase receptor B (TrkB), BDNF
triggers TrkB autophosphorylation to initiate several signaling
cascades, including the PI3K/Akt, Ras/Raf/ERK, and PLCg/
PKC pathways (Numakawa et al., 2010). It has been reported
that infusion of BDNF into the lateral ventricle suppresses food
intake and body weight gain in rats (Pelleymounter et al.,
1995). In both humans and mice, BDNF/TrkB ablation or muta-
tion causes hyperphagia and obesity phenotype (Gray et al.,Chemistry & Biology 22, 32006; Yeo et al., 2004; Kernie et al., 2000). Since selective deple-
tion of the BDNF gene in the neurons of the ventral medial hypo-
thalamus (VMH) and dorsomedial hypothalamus (DMH) is
sufficient to induce hyperphagia and increase body weight
gain in mice, it is also suggested that the hypothalamus is the
major target site for BDNF to perform its anorexic activity (Unger
et al., 2007). However, the specific action site of BDNF to inhibit
food intake is mysterious as exogenous delivery of BDNF to the
paraventricular hypothalamus (PVH), VMH, or medial nucleus
tractus solitarius (mNTS) can all suppress calorie intake (Rios,
2013). Interestingly, administration of BDNF into db/db mice
also transiently increases energy metabolism via an unclear
mechanism (Nakagawa et al., 2000). Thus, manipulating
BDNF/TrkB signaling may represent a potential strategy in
combating or preventing the development of obesity. However,
the beneficial role of chronic TrkB activation in preventing the
development of long-lasting diseases such as obesity has not
been tested because of the short half-life and nonbioavailable
nature of BDNF (Poduslo and Curran, 1996), which hampers
the development of a BDNF/TrkB-based therapeutic strategy.
To search for an orally bioavailable BDNF mimetic, we have
identified 7,8-dihydroxyflavone (7,8-DHF) as a specific TrkB
agonist, which induces TrkB dimerization and activation of its
downstream signaling molecules, including Akt and ERK (Jang
et al., 2010). Like BDNF, application of 7,8-DHF promotes the
survival of cortical, hippocampal, retinal ganglion, and spiral
ganglion neurons and prevents various oxidative or excitotoxic-
ity-induced cell death in a TrkB-dependent manner (Jang et al.,
2010; Gupta et al., 2013; Yu et al., 2013). Hence, 7,8-DHF can
be applied to alleviate the symptoms of neurological disorders
related to BDNF deficiency. For example, administration of
7,8-DHF enhances emotional learning, prevents the return of
fear in extinction-trainedmice (Baker-Andresen et al., 2013), pre-
vents cognitive defects in a rat model of posttraumatic stress
disorder (Andero et al., 2012), and elongates the lifespan and
alleviates the pathological conditions of Rett syndrome (Johnson
et al., 2012). 7,8-DHF also displays impressive therapeutic effi-
cacy in animal models of Parkinson disease (Jang et al., 2010),
Alzheimer disease (Zhang et al., 2013), and Huntington disease
(Jiang et al., 2013). Furthermore, 7,8-DHF demonstrates a55–368, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 355
promising effect in enhancing axon regeneration in BDNF condi-
tional knockout (cKO) mice but not in TrkB cKO mice (English
et al., 2013). These studies strongly support that 7,8-DHF is a
bioavailable TrkB agonist, which could be used as a molecular
tool to study the beneficial role of chronic TrkB activation in dis-
eases such as obesity.
We report here that chronic activation of TrkB by 7,8-DHF can
be used as an effective method to prevent excess body weight
gain during energy surplus. Moreover, we found that activation
of muscular TrkB by 7,8-DHF is sufficient to ameliorate the
development of obesity and its associated diabetes in female
animals, suggesting peripheral TrkB signaling is equally impor-
tant as that in the CNS to control systemic energy metabolism.
RESULTS
7,8-DHF Consumption Prevents the Development of
Diet-Induced Obesity in Female Mice
In order to test if 7,8-DHF can control body weight, we included
7,8-DHF in the drinking water (final concentration 0.16 mg/ml) of
C57BL/6 mice fed with chow or a high-fat diet (HFD, 45% kcal).
7,8-DHF administration did not cause significant toxicity or un-
desirable side effects as revealed by normal complete blood
counts (Table S1) and tissue histology examinations (Liu et al.,
2010). While female mice consuming 7,8-DHF displayed
reduced body weight gain under HFD feeding, 7,8-DHF did not
significantly decrease the body weight of mice fed with a chow
diet (Figure 1A). Unexpectedly, 7,8-DHF was not effective in pre-
venting body weight gain in male mice under HFD feeding either
(Figure S1). Therefore, we performed the subsequent analyses in
female mice only. HFD-fed female animals exhibited a drastic in-
crease in inguinal white adipose tissue (WAT) mass, which was
substantially reduced after 7,8-DHF treatment (Figure 1B). The
adipocytes in 7,8-DHF-treated mice were also smaller (Figures
1C, lower panels, and 1D). Since 7,8-DHF stimulation did not
inhibit adipogenesis in 3T3-L1 preadipocytes (Figure S2), the
reduction in adipocyte size or mass is possibly a secondary
effect of 7,8-DHF treatment. Circulating leptin (Figure 1E) and
tumor necrosis factor alpha (TNFa) (Figure 1F) concentrations
were lower after 7,8-DHF treatment. Hepatic concentrations of
cholesterol, triglyceride (TG), and free fatty acid (FFA) were
significantly diminished in 7,8-DHF-treated animals under HFD
feeding (Figures 1G–1I), whichwas in alignment with the reduced
hepatic steatosis observed (Figure 1C, upper panels). Similarly,
the TG and FFA concentrations in muscle were also decreased
in the 7,8-DHF-treated animals (Figures 1H and 1I). Thus, treat-
ment of mice with 7,8-DHF reduces diet-induced body weight
gain and lipid accumulation in ectopic tissue.
7,8-DHF Treatment Improves Insulin Sensitivity and
Glucose Tolerance
Insulin resistance is one of the most prominent complications of
obesity. Since we found that 7,8-DHF is able to prevent diet-
induced obesity, we then askedwhether the treatment affects in-
sulin sensitivity. 7,8-DHF treatment for 20 weeks significantly
diminished fasting hyperglycemia inHFD-fed animals (Figure 2A).
Obesity-induced hyperinsulinemia was also alleviated after 7,8-
DHF consumption (Figure 2B), suggesting improved insulin
sensitivity. Indeed, HFD-fed mice treated with 7,8-DHF revealed356 Chemistry & Biology 22, 355–368, March 19, 2015 ª2015 Elseviebetter glucose clearance during the glucose tolerance test
(Figure 2C). We further examined systemic insulin sensitivity in
7,8-DHF-treated mice using the gold standard hyperinsuline-
mic-euglycemic clamp assay. As shown in Figures 2D and 2E,
the glucose infusion rate was significantly higher in 7,8-DHF-
treated mice than vehicle-treated animals, indicating an
improved systemic insulin sensitivity. Insulin infusion also medi-
ated higher hepatic glucose suppression and muscular glucose
uptake in 7,8-DHF-treated mice (Figures 2F–2H). Concurring
with these results, Akt phosphorylation was evidently higher in
the liver and muscle of HFD-fed mice upon 7,8-DHF treatment,
although upstream insulin receptor activity was not affected (Fig-
ures 2I and 2J). Hence, 7,8-DHF treatment mitigates obesity-
induced insulin resistance.
7,8-DHF Treatment Increases Energy Expenditure
Since BDNF is an anorexigenic factor that suppresses food
intake, we next sought to determine if 7,8-DHF treatment could
induce hypophagia. We found that mice fed with HFD and 7,8-
DHF for 20 weeks contained less total body fat on body compo-
sition analysis (Figure 3A). Total lean mass was also decreased
(Figure 3B).When fat and leanmasseswere normalizedwith total
bodyweight, the percentage of lean bodymasswas comparable
between the two treatment groups (52.6% ± 3.3% in the control
group versus 59.0% ± 4.1% in the 7,8-DHF-treated group),
whereas the percentage of fat mass was significantly reduced
in 7,8-DHF-treated animals (27.0% ± 1.7% in the control group
versus 19.6% ± 3.2% in the 7,8-DHF-treated group, P < 0.05,
Student’s t test, n = 6). To our surprise, total food intake at night
was higher in mice after 7,8-DHF treatment (Figure 3C). On the
other hand, total water uptake was prominently reduced in ani-
mals treated with 7,8-DHF (Figure 3D), probably because of
the unfavorable taste of 7,8-DHF in the water. Locomotor activity
was not changed after 7,8-DHF consumption (Figure 3E). Intes-
tinal lipid absorption was comparable between the two groups,
as the amount of residual lipid content in the feceswas not signif-
icantly altered by 7,8-DHF (Figure S3). Presumably, the reduc-
tion in body weight in 7,8-DHF-treated mice under HFD feeding
is not a result of decreased food intake or lipid absorption but
enhanced energy metabolism. Indeed, both resting and nonrest-
ing energy expenditure were higher in the animals treated with
7,8-DHF (Figure 3F). Elevated oxygen consumption and carbon
dioxide production were also detected after 7,8-DHF-treatment
(Figures 3G and 3H), indicating an overall increase in metabolic
rate after chronic 7,8-DHF consumption. On the other hand,
the respiratory exchange ratio (RER) was not significantly
changed in mice fed with HFD and 7,8-DHF, suggesting that
the utilization balance between glucose and lipid was not
affected (Figure 3I).
Gene Expression Analysis of 7,8-DHF-Treated Muscle
and Liver
To dissect the molecular mechanisms underlying the antiobesity
effect of 7,8-DHF, we performed a comprehensive analysis
of the gene expression pattern in hindlimb skeletal muscle
(a mixture of the soleus and gastrocnemius muscles) and liver
of mice fed with HFD and 7,8-DHF. Microarray screening indi-
cated that 22 hepatic genes were significantly upregulated
and 14 hepatic genes were downregulated more than 2-fold inr Ltd All rights reserved
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Figure 1. 7,8-DHF-Treated Female Mice Are Resistant to Diet-Induced Obesity
(A) Growth curve of 8-week-old female mice fed with different combinations of diets (*P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA versus the same diet
feeding, n = 8–10).
(B) Organ weight of female mice that have been fed with HFD and 7,8-DHF for 20 weeks (**P < 0.01, Student’s t test, n = 5).
(C) Pictures of H&E staining of inguinal WAT and liver sections from female mice that have been fed with HFD and 7,8-DHF for 20 weeks. Representative results of
four different mice from each treatment are shown. Scale bar represents 50 mm.
(D) Adipocyte size of inguinal fat pad isolated from female mice that have been fed with HFD and 7,8-DHF for 20 weeks (n = 4).
(E) Circulating leptin concentration in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (*P < 0.05, Student’s t test, n = 6).
(F) Circulating TNFa concentration in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (*P < 0.05, Student’s t test, n = 6).
(G) Tissue cholesterol content in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (*P < 0.05, Student’s t test, n = 6).
(H) Tissue TG content in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (**P < 0.01, Student’s t test, n = 6).
(I) Tissue FFA content in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (**P < 0.01, Student’s t test, n = 6).
See also Figures S1 and S2. Results were presented as means ± SEM.7,8-DHF-treated liver when compared with the control group
(Table S2). Of these genes, only two are related to energy or fatty
acid metabolisms (Figure 4A; Table S2). The number of induced
genes was much higher in the skeletal muscle after 7,8-DHF
treatment. It was found that 58 muscle genes were significantly
upregulated and 28 muscle genes were downregulated (Table
S3). Twenty-three of these 86 genes are involved in glucose uti-Chemistry & Biology 22, 3lization, fatty acid oxidation, or energy production (Figure 4A;
Table S3). Some of these genes, e.g. fatty acid elongase Elovl6
and bone morphogenetic protein 5 (Bmp5), have been reported
to be important factors in regulating energy expenditure (Matsu-
zaka et al., 2007; Tseng et al., 2008). We validated themicroarray
findings by selectively testing those genes that have been re-
ported in regulating glucose or fatty acid metabolism using55–368, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 357
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Figure 2. Alleviated Obesity-Induced Insulin Resistance in 7,8-DHF-Treated Female Mice
(A) Blood glucose concentration in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (*P < 0.05, Student’s t test, n = 6).
(B) Circulating insulin concentration in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (*P < 0.05, **P < 0.01, Student’s t test, n = 6).
(C) Glucose tolerance test in female mice that have been fed with HFD and 7,8-DHF for 20 weeks (*P < 0.05, two-way ANOVA, n = 5).
(D) Glucose infusion rate in female mice that have been fedwith HFD and 7,8-DHF for 20 weeks during the hyperinsulinemic-euglycemic clamp experiment (n = 6).
(E) Average glucose infusion rate during the hyperinsulinemic-euglycemic clamp experiment (*P < 0.05, Student’s t test, n = 6).
(F) Hepatic glucose production of female mice that have been fed with HFD and 7,8-DHF for 20 weeks during the hyperinsulinemic-euglycemic clamp (***P <
0.001, Student’s t test, n = 6).
(G) Percentage of insulin-suppressed glucose production from liver during the hyperinsulinemic-euglycemic clamp (*P < 0.05, Student’s t test, n = 6).
(H) Glucose uptake in various tissues during the hyperinsulinemic-euglycemic clamp (*P < 0.001, Student’s t test, n = 5).
(I) Enhanced insulin-induced signaling in femalemice that have been fedwith HFD and 7,8-DHF for 20weeks. The phosphorylations of IR (first panel) and Akt (third
panel) were determined using specific antibodies as indicated. The expression of total IR (second panel) and Akt (fourth panel) were determined to show equal
loading.
(J) Quantification of the band intensity shown in (I) (*P < 0.05, Student t test, n = 3).
Results were presented as means ± SEM.real-time PCR. In agreement with the microarray data, expres-
sion of major urinary protein 1 (Mup1) (Zhou et al., 2009), perilipin
1 (Plin1) (Sztalryd et al., 2003), and the b subunit of cyclic AMP
(cAMP)-dependent protein kinase type II (Prkar2b) (Cummings
et al., 1996) was significantly higher in 7,8-DHF-treated muscle.
On the other hand, 7,8-DHF-treatedmuscle expresses lessmito-358 Chemistry & Biology 22, 355–368, March 19, 2015 ª2015 Elseviechondrial NADH dehydrogenase 6 (ND6) (Bai and Attardi, 1998)
than the control (Figure 4B). Interestingly, we found that expres-
sion of uncoupling protein 1 (UCP1), a mitochondrial protein that
is responsible for nonshivering thermogenesis in brown adipose
tissue (BAT) (Aquila et al., 1985; Cannon and Nedergaard, 2004),
was robustly increased in the muscle of mice after 7,8-DHFr Ltd All rights reserved
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Figure 3. 7,8-DHF Treatment Increases
Energy Expenditure in HFD-Fed Female Mice
(A) Total fat mass of female mice that have been
fed with HFD and 7,8-DHF for 20 weeks as
measured by indirect calorimetry (**P < 0.01, Stu-
dent’s t test, n = 6).
(B) Total lean mass of female mice that have
been fed with HFD and 7,8-DHF for 20 weeks
measured by indirect calorimetry (***P < 0.001,
Student’s t test, n = 6).
(C) Food intake of female mice that have been fed
with HFD and 7,8-DHF for 20 weeks during the
metabolic cage measurement (*P < 0.05, Student’s
t test, n = 6).
(D) Water uptake of female mice that have been fed
with HFD and 7,8-DHF for 20 weeks during the
metabolic cage measurement (*P < 0.05, Student’s
t test, n = 6).
(E) Locomotor activity of female mice that have been
fed with HFD and 7,8-DHF for 20 weeks during the
metabolic cage measurement (n = 6).
(F) Energy expenditure of female mice that have
been fed with HFD and 7,8-DHF for 20 weeks during
the metabolic cage measurement (*P < 0.05, Stu-
dent’s t test, n = 6).
(G) Oxygen consumption of female mice that have
been fed with HFD and 7,8-DHF for 20 weeks during
the metabolic cage measurement (*P < 0.05, Stu-
dent’s t test, n = 6).
(H) Carbon dioxide production from femalemice that
have been fed with HFD and 7,8-DHF for 20 weeks
during the metabolic cage measurement (**P < 0.01,
Student’s t test, n = 6).
(I) RER of female mice that have been fed with HFD
and 7,8-DHF for 20 weeks during the metabolic
cage measurement (n = 6).
See also Figure S3. Results were presented as
means ± SEM.treatment (Table S3; Figure 4C). The increased UCP expression
was isoform specific as expression of other UCP isoforms (UCP2
and UCP3) was not altered in response to 7,8-DHF treatment
(Figure 4C). We further confirmed the elevated UCP1 expression
in 7,8-DHF-treated muscle using immunoblotting. As shown in
Figure 4D, expression of UCP1 protein was specifically induced
in the muscle of 7,8-DHF-treated mice but not in liver or WAT.Chemistry & Biology 22, 355–368, March 19, 2017,8-DHF Treatment Activates
AMPK/ACC Signaling
Since ectopic UCP1 overexpression in
skeletal muscle increases systemic energy
expenditure and lipid utilization, leading to
a reduction in gain of body weight of mice
under HFD feeding (Li et al., 2000; Klaus
et al., 2005; Neschen et al., 2008), we
thus examined if the signal transduction
pathway for lipid oxidation was also
enhanced in 7,8-DHF-treated animals.
HFD-fed mice with 7,8-DHF consumption
displayed a significant increase in AMP-
activated protein kinase (AMPK) phosphor-
ylation in the muscle but not in the liver or
WAT (Figure 5A, first panel). In line withthis observation, phosphorylation of AMPK substrate acetyl-
coenzyme A carboxylase (ACC) was upregulated in the muscle
(Figure 5A, third panel). ACC phosphorylation was also
increased in liver and WAT. However, since the total amount of
ACC was augmented in all tested tissues of 7,8-DHF-treated
mice (Figure 5A, fourth panel), the ratio of phospho-ACC to total
ACC was only significantly elevated in the muscle (Figure 5B,5 ª2015 Elsevier Ltd All rights reserved 359
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Figure 4. Gene Expression and Signaling
Analyses in 7,8-DHF-Treated Female Mice
(A) Classification of 7,8-DHF-induced genes in the
liver and hindlimb muscle isolated from female
mice that have been fed with HFD and 7,8-DHF for
20 weeks.
(B) Expression of representative skeletal muscle
genes in female mice that have been fed with HFD
and 7,8-DHF for 20 weeks as measured by real-
time PCR analysis (*P < 0.05, ***P < 0.01, Student’s
t test, n = 3).
(C) Expression of various UCP isoforms in the
skeletal muscle of female mice that have been fed
with HFD and 7,8-DHF for 20 weeks (***P < 0.01,
Student’s t test, n = 3).
(D) Expression of UCP1 in various tissues isolated
from female mice that have been fed with HFD and
7,8-DHF for 20 weeks.
Results were presented as means ± SEM.middle panel). Keipert et al. (2013) have reported that ERK phos-
phorylation was upregulated in the muscle of UCP1 transgenic
mice, which is possibly a protective response to increased
oxidative stress. We also observed that ERK phosphorylation
was highly escalated in the liver and muscle of 7,8-DHF-treated
mice (Figure 5A, fifth panel and Figure 5B). Interestingly, expres-
sion and phosphorylation of cAMP response element-binding
protein (CREB), the transcription factor that controls UCP1 tran-
scription (Rim and Kozak, 2002), were increased in liver, muscle,
and WAT of 7,8-DHF-treated mice (Figure 5A, seventh and
eighth panels). Thus, our immunoblotting analysis indicates
that the lipid oxidation pathways are activated in the skeletal
muscle of mice after chronic 7,8-DHF consumption.
Skeletal Muscle TrkB Is the Major Target of 7,8-DHF to
Mediate its Antiobesity Effect
Although we observed that TrkB phosphorylation was increased
in the hypothalamus of mice under chronic 7,8-DHF treatment
(Figure S4), food intake was not suppressed in the 7,8-DHF-
treated animals (Figure 3C), suggesting that the hypothalamus
may not be the target tissue for 7,8-DHF to exert its antiobesity
function. We thus hypothesized that muscle TrkB is the
major target of 7,8-DHF for preventing the development of
obesity under HFD feeding. We tested this hypothesis by feeding
7,8-DHF to genetically engineered mice with muscle-specific
TrkB deletion. By mating transgenic mice that encompass
two flox elements flanking the first coding exon of the Ntrk2
gene and transgenic mice carrying a muscle creatine kinase360 Chemistry & Biology 22, 355–368, March 19, 2015 ª2015 Elsevier Ltd All rights reserved(MCK)-promoter-driven Cre recombi-
nase, we generated muscle-specific
TrkB knockout (MTKO) mice (Figure 6A).
Genomic (Figure 6B) and RT-PCR (Fig-
ure 6C) analyses confirmed the tissue-
specific deletion of the Ntrk2 gene in the
skeletal muscle. Western blot analysis
also indicated that the amount of TrkB
protein was significantly reduced in the
skeletal muscle of MTKO mice (Fig-
ure 6D). The residual signals in Figures6C and 6D might result from the TrkB of the muscle-innervated
sciatic nerve (Funakoshi et al., 1993). When female MTKO mice
were fed with HFD and H2O for 16 weeks, their body weight
increased to the same extent as the wild-type (WT) animals;
however, 7,8-DHF treatment significantly reduced body weight
gain in WT but not MTKO mice (Figure 6E), although hypotha-
lamic TrkB receptors could still be activated in MTKO mice (Fig-
ure S4). Moreover, no elevated AMPK and ACC phosphorylation
was detected in 7,8-DHF-treated MTKO muscle, as the ratios of
phosphoprotein/total protein remained comparable (Figures 6F
and 6G). These results suggest that the muscle TrkB receptor
is indispensable for 7,8-DHF to exert its antiobesity function.
7,8-DHF Increases Lipid Oxidation andUCP1Expression
in Cultured Muscle Cells
Our in vivo data indicate that 7,8-DHF might act on muscle TrkB
to protect animals from developing diet-induced obesity. We
further confirmed these results using an in vitro system. As ex-
pected, phosphorylation of TrkB and its downstream target Akt
was increased in differentiated C2C12 myotubes upon 7,8-
DHF treatment (Figure 7A), suggesting that TrkB signaling is
intact in the C2C12 cells. In alignment with the in vivo data,
increased AMPK and ACC phosphorylation was detected in
7,8-DHF-stimulated C2C12 myotubes in a time- (Figure 7B)
and dose-dependent (Figure 7C) manner. Accordingly, 7,8-
DHF stimulation caused a significant elevation of lipid oxidation
in C2C12 myotubes (Figure 7D). Nevertheless, 7,8-DHF did not
activate AMPK directly as the presence of 7,8-DHF did not
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Figure 5. 7,8-DHF Treatment Enhances AMPK/ACC Signaling in HFD-Fed Female Mice
(A) Immunoblot analysis of various tissues isolated from female mice that have been treated with 7,8-DHF for 20 weeks.
(B) Quantification of the protein phosphorylation shown in (A) (*P < 0.05, Student’s t test, n = 3).
See also Figure S4. Results were presented as means ± SEM.enhance AMPK activities in the in vitro kinase assay (Figure S5).
Inhibiting the kinase activity of TrkB using the specific inhibitor
K252a (Tapley et al., 1992) diminished BDNF- or 7,8-DHF-
induced AMPK and ACC phosphorylation (Figure 7E). On
the other hand, C2C12 myotubes overexpressing TrkB dis-
played higher 7,8-DHF- or BDNF-induced AMPK and ACC
phosphorylation (Figure 7F). We also found that 7,8-DHF
decreased the cellular concentration of ATP and ADP (Figure 7G)
but increased the ADP/ATP ratio (Figure 7H) in C2C12myotubes.
This elevation of the ADP/ATP ratio could be reduced in the
presence of K252a (Figure 7I), suggesting that 7,8-DHF acts on
TrkB to alter the concentration of cellular adenosine phosphate.
Lastly, immunoblotting analysis validated that UCP1 expression
and CREB phosphorylation in C2C12 were elevated after 7,8-
DHF treatment (Figure 7J). Our results suggest that 7,8-DHF
can directly alter the energy metabolism pathways in muscle
cells.
DISCUSSION
Most studies on the antiobesity activity of BDNF/TrkB focus on
their anorexic roles in the CNS, with little attention paid to other
tissues, although both BDNF and TrkB mRNAs could be
detected in peripheral organs such as muscle, pancreas, heart,
kidney, and ovary (Shelton et al., 1995). In fact, BDNF synthesisChemistry & Biology 22, 3in muscle cells is a dynamic process, which responds actively to
exercise stimulation (Cuppini et al., 2007). Matthews et al. (2009)
further demonstrated in vitro that stimulation of L6 muscle cells
with BDNF enhanced AMPKactivity via an unknownmechanism,
suggesting that BDNF is a beneficial mediator of energy
metabolism in muscle. Conceivably, activation of BDNF/TrkB
signaling in muscle may provide a beneficial outcome to prevent
obesity, but this hypothesis has not been proved in vivo because
the nonbioavailable nature of BDNF and the tedious administra-
tion protocols do not favor any long-term study. Using the BDNF
mimetic, 7,8-DHF, identified by our group, and MTKO mice, we
have provided compelling in vivo evidence to support the idea
that muscular TrkB is equally important to CNS TrkB in control-
ling body weight gain. We found that chronic administration of
7,8-DHF to mice ameliorates diet-induced obesity by activating
the TrkB in muscle. Because the food intake and locomotor ac-
tivities of the tested mice were not suppressed after 7,8-DHF
treatment, together with the fact that 7,8-DHF consumption fails
to protect MTKO mice from developing obesity under HFD
feeding, we propose that 7,8-DHF acts on muscle tissue to
enhance total energy expenditure. Indeed, our in vitro studies
on C2C12 myotubes concur with the in vivo findings that 7,8-
DHF stimulation elicits increased AMPK activity, lipid oxidation,
and UCP1 expression. Presumably, activation of muscle TrkB
by 7,8-DHF increases UCP1 expression, which results in an55–368, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 361
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Figure 6. Muscle TrkB Is the Major Target of 7,8-DHF to Prevent Diet-Induced Obesity
(A) A schematic representation of mouse TrkB deletion using loxP/Cre recombination. The location of loxP sites were marked as solid triangles. Locations of the
primers used in the genomic PCR are indicated by the arrows.
(B) Deletion of TrkB in MTKO mice. Genomic DNA were isolated from the tail tip of female mice and used to perform PCR.
(C) Reduced TrkB expression in the skeletal muscle of MTKO mice. Total RNA was isolated from various tissues of female MTKO mice and used to generate
cDNA. PCR was then performed to determine TrkB expression. Expression of GAPDH was also tested as control.
(D) MTKO mice have less TrkB protein in the skeletal muscle cell lysates were prepared from various tissues of female MTKO mice and the amount of TrkB
proteins was examined using immunoblotting.
(E) Growth curve of 8-week-old female mice fed with HFD and 7,8-DHF in the drinking water (0.16 mg/ml) (*P < 0.05, **P < 0.01, two-way ANOVA, n = 7–10).
(F) Immunoblotting analysis of AMPK and ACC phosphorylation in muscle isolated from female MTKO mice that have been treated with 7,8-DHF for 16 weeks.
(G) Quantification of the protein phosphorylation shown in (F) (n = 3).
Results were presented as means ± SEM.enhanced uncoupling reaction and a reduction in the cellular
energy supply, leading to activation of AMPK and enhanced lipid
oxidation, and eventually reduced body weight gain. Neverthe-
less, we could not exclude that other cascades, such as ERK
signaling, are also involved in the antiobesity and antidiabetic ac-362 Chemistry & Biology 22, 355–368, March 19, 2015 ª2015 Elsevietion of 7,8-DHF because Fu et al. (2010) reported that dietary
intake of genistein, a structurally related flavonoid, significantly
improved hyperglycemia, glucose tolerance, and blood insulin
levels in streptozotocin-induced diabetic mice via ERK activa-
tion. In short, our findings suggest that modulating muscler Ltd All rights reserved
BDNF/TrkB signaling may represent a promising strategy for
obesity therapy.
One of the key findings in the current study is that activation of
the TrkB signaling in muscle leads to the expression of UCP1.
UCP1 is a mitochondrial protein that disrupts the electrochemi-
cal gradient across the inner mitochondrial member, causing
energy derived from oxidative phosphorylation to be released
as heat (Cannon and Nedergaard, 2004). While this protein is
highly expressed in BAT, ectopic expression of UCP1 in muscle
enhances systemic energy expenditure (Klaus et al., 2005), ele-
vates AMPK activation and lipid oxidation (Neschen et al.,
2008), decreases muscle ATP and ADP content (Han et al.,
2004), prevents the development of diet-induced obesity, and
alleviates obesity-associated diabetes (Li et al., 2000). Total
body lean mass is also reduced in UCP1 transgenic mice, which
is possibly a result of lower energy efficiency due to the
enhanced uncoupling reaction (Klaus et al., 2005). These pheno-
types in UCP1 transgenic mice closely resemble our observa-
tions in mice fed with HFD and 7,8-DHF, which provides strong
support for our conclusion that enhanced UCP1 is the keymech-
anism for the beneficial action of BDNF/TrkB signaling in
muscular energy metabolism. Although the molecular mecha-
nism of BDNF-induced UCP1 expression is unclear, promoter
analysis suggested that the human UCP1 gene contains several
cAMP responsive elements (del Mar Gonzalez-Barroso et al.,
2000). Rim and Kozak (2002) further provide in vitro evidence
that CREB controls UCP1 transcription. Since CREB is one of
the major downstream signaling molecules of the BDNF/TrkB
pathway (Finkbeiner et al., 1997) and we also found that total
expression as well as phosphorylation of CREB were upregu-
lated in 7,8-DHF-treated muscle, it is reasonable to deduce
that BDNF induces UCP1 expression in muscle via activating
CREB.
Interestingly, 7,8-DHF treatment controls the development of
obesity in a sex- and metabolic status-specific manner; only
female animals under HFD feeding benefit from the BDNF
mimetic compound. In alignment with our findings, subcutane-
ous injection of BDNF improves body weight gain and energy
expenditure only in obese db/db but not in normal mice (Kernie
et al., 2000). Sex dimorphism in the BDNF response is
commonly observed in mice. For instance, change of body
composition in female animals is more sensitive to BDNF as
female BDNF cKO mice display a higher increase in body fat
composition (Camerino et al., 2012). In addition, while male
BDNF cKO mice exhibit hyperactivity but normal depression-
related behaviors, female BDNF cKO mice display normal loco-
motor activity but a striking increase in depression-like
behavior (Monteggia et al., 2007). A recent study also reported
that 7,8-DHF has more profound activity in protecting hypoxia
ischemia-mediated neuronal death and white matter injury in
female mice than in male mice (Uluc et al., 2013). The molecular
mechanism for this sex dimorphism is unknown but it is sug-
gested that the presence of sex-specific hormones may pro-
vide a possible explanation. For example, estrogen has been
proposed to enhance BDNF functionality via crosstalking with
TrkB signaling (Spencer et al., 2008). Presumably, these inter-
acted sex-hormone-BDNF pathways are synergistic in female
mice but are less relevant in determining the metabolic pheno-
type in males.Chemistry & Biology 22, 3Previous studies have reported that administration of BDNF
into obese animals suppresses food intake via the hypothalamus
(Wang et al., 2010). However, we did not observe any suppres-
sion of food intake in mice after chronic 7,8-DHF treatment.
Rather, these animals display enhanced food intake. As such,
7,8-DHF may not act on hypothalamus neurons to control food
intake as BDNF does. There are several explanations for these
discrepant findings. First, the route of administration in our study
is different from previous studies. In this report, 7,8-DHF was
administrated to the animals via drinking water, and in some
animals it will be metabolized in the gastrointestinal track or
the liver (Liu et al., 2013), whereas BDNF administration in other
studies was performed by either subcutaneous or intracerebral
injections (Tsuchida et al., 2001). Since the brain clearance
rate, diffusion rate, and metabolism may be different between
BDNF and 7,8-DHF, the amount of 7,8-DHF that reached the hy-
pothalamus in our study may not be high enough to trigger the
same physiological response as BDNF. Alternatively, the cellular
signaling events induced by BDNF and 7,8-DHFmay be different
although both of them are TrkB agonists. It is possible that acti-
vation of TrkB by BDNF or 7,8-DHF may induce differential
receptor phosphorylation patterns, thus leading to the inducer-
specific cellular response. Collectively, our results identify that
the BDNF/TrkB signaling pathway in muscle controls lipid oxida-
tion and energy expenditure and that the use of the BDNF
mimetic 7,8-DHF displays great potential in treating obesity.
SIGNIFICANCE
Obesity is a major risk factor for a number of diseases
including diabetes, cardiovascular diseases, liver steatosis,
and even certain types of cancer. The increasing prevalence
of obesity thus puts tremendous pressure on public health
and economic systems. Although a considerable amount
of work has been invested in developing new medications
for obesity treatment, only a few effective pharmacotherapy
strategies are available on the market. Chronic activation of
TrkB is a potential method to treat or prevent obesity, but the
hypothesis has not been validated because of the short half-
life and nonbioavailable nature of BDNF. Using the BDNF
mimetic, 7,8-DHF, as the molecular probe, we found that
chronic activation of muscular TrkB modulates cellular en-
ergy expenditure and prevents the development of excess
body weight gain in female mice under energy surplus.
These results reveal the molecular mechanism of TrkB-
regulated cellular energymetabolism and prove that chronic
activation of muscular TrkB by 7,8-DHF can be used as a po-
tential strategy against the development of obesity.
EXPERIMENTAL PROCEDURES
Animal Experiments
C57BL/6J mice were obtained from Jackson Laboratory. Eight-week-old ani-
mals were used in our experiments. Mice were housed in environmentally
controlled conditions with a 12-hr light/dark cycle and had free access to stan-
dard rodent pellet food and water. The animal protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) of Emory University or
Vanderbilt University. Animal care was given in accordance with institutional
guidelines.
Blood glucose levels were measured by ACCU-CHEK Advantage Blood
Glucose Meter (F. Hoffmann-La Roche). Serum insulin and leptin were55–368, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 363
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Figure 7. 7,8-DHF Treatment Enhances Lipid Oxidation, ADP/ATP Ratio, and UCP1 Expression in Cultured Muscle Cells
(A) 7,8-DHF induces TrkB phosphorylation in muscle cells. Differentiated C2C12 myotubes were stimulated with 7,8-DHF (1 mM) for various time intervals as
indicated. Cell lysates were then collected and the phosphorylation of TrkB (first panel) and Akt (third panel) was examined. Total TrkB (second panel) and Akt
(fourth panel) were also verified.
(B) 7,8-DHF activates AMPK and ACC inmuscle cells. Differentiated C2C12myotubes were stimulatedwith 7,8-DHF (1 mM) for various time intervals as indicated.
Cell lysates were then collected and the phosphorylation of AMPK (first panel), ACC (third panel), and Akt (fifth panel) was examined. Total AMPK (second panel),
ACC (fourth panel), and Akt (sixth panel) were also verified.
(legend continued on next page)
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measured by ELISA (Crystal Chem). Cholesterol, TG, and FFA levels in tissues
or serum were measured using the Cholesterol/Cholesteryl Ester Quantitation
Colorimetric Kit, Triglyceride Quantification Colorimetric Kit, and Free Fatty
Acid Quantification Colorimetric Kit, respectively (BioVision). Serum TNFa
was measured by ELISA (BD Biosciences). A glucose tolerance test was per-
formed on mice after peritoneal injection of D-glucose (2 g/kg of body weight).
Generation of MTKO Mice
MTKO mice were generated by mating transgenic mice that encompass two
flox elements flanking the first coding exon of Ntrk2 gene and transgenic
mice carrying an MCK-promoter-driven Cre recombinase (Jackson Labora-
tory) until homozygosity. Genotyping was performed by PCR using genomic
DNA isolated from the tail tip. PCR was performed using a combination of
primers 50-ACACACACAGTATATTTTACC-30 (forward) and 50-CAAGAAGTCA
GAGACCAGAGAGA-30 (reverse) for TrkB flox allele; and 50-CCTGGAAAA
TGCTTCTGTCCGTTTGCC-30 (forward) and 50- CCTGGAAAATGCTTCTGT
CCGTTTGCC-30 (reverse) for Cre transgene.
Chemicals and Reagents
C2C12, 3T3-L1, and HEK293 cells were purchased from ATCC and main-
tained as instructed. Differentiation of C2C12 was performed as reported (Bur-
attini et al., 2004). Transfection in C2C12 was performed using DharmaFECT1
as instructed (Thermo Scientific). 7,8-DHF was purchased from Tokyo Chem-
ical Industry. HFD (40% kcal) was obtained from Research Diet. Human insulin
was obtained from Eli Lilly. Other chemicals were purchased from Sigma-
Aldrich. Antibodies against pAkt S473, IR, pIR Y1150/1151 (#3024), pAMPKa
T172 (#2535), AMPKa (#2603), pACC S79 (#3661), ACC (#3676), pERK T202/
Y204 (#9106), ERK (#9102), pCREB S133 (#9198), CREB (#4820), and TrkB
(4603) were purchased from Cell Signaling. Anti-Akt1 (sc5298) and anti-pTrkB
Y706 (sc135645) antibodies were obtained from Santa Cruz Biotechnology.
Anti-UCP1 antibody (ab155117) was obtained from Abcam. Anti-tubulin anti-
body (T6074) was obtained from Sigma-Aldrich.
Western Blot Analysis
Tissues or cells were homogenized in lysis buffer containing 50 mM Tris
(pH 7.4), 40 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1.5 mM Na3VO4,
50 mM NaF, 10 mM sodium pyrophosphate, 10 mM sodium b-glycerophos-
phate, 1 mM phenylmethylsulfonyl fluoride, and 13 protease inhibitor cocktail
(Sigma-Aldrich). Cell debris was removed by centrifugation and the superna-
tant (cleared cell lysate) was collected for immunoblotting.Western blot results
were visualized using Pierce ECL Western Blotting Substrate (Thermo
Scientific).(C) Dose-dependent induction of AMPK and ACC phosphorylations in muscle ce
with 7,8-DHF at various concentrations for 24 hr. Cell lysates were then collect
examined. Total AMPK (second panel) and ACC (fourth panel) were also verified
(D) 7,8-DHF increases lipid oxidation in cultured muscle cells. Differentiated C2C1
and the palmitic acid oxidation rate was then measured (*P < 0.05, one-way ANO
(E) Inhibition of TrkB abolishes 7,8-DHF or BDNF-induced AMPK activation. Diff
(10 nM) for 1 hr followed byBDNF (100 ng/ml) for 1 hr or 7,8-DHF (1 mM) for 2 or 6 hr
ACC (third panel), and TrkB (fifth panel) was examined. Total AMPK (second pan
(F) Overexpression of TrkB augments 7,8-DHF-induced AMPK activity. Differen
followed by 7,8-DHF (1 mM) for 24 hr. Cell lysates were then collected and the ph
AMPK (second panel) and ACC (fourth panel) were also verified.
(G) 7,8-DHF stimulation reduces cellular ADP and ATP concentration. Differentiate
24 hr. Cell lysates were collected and the cellular concentration of ADP and ATPw
(H) 7,8-DHF stimulation increases the cellular ADP/ATP ratio. Differentiated C2C1
Cell lysates were collected and the cellular concentration of ADP and ATP was th
(I) Inhibition of TrkB kinase suppresses the 7,8-DHF-elevated ADP/ATP ratio. Diffe
by 7,8-DHF (1 mM) for 24 hr. Cell lysates were collected and the cellular concent
ANOVA, n = 6).
(J) 7,8-DHF increases UCP1 expression in muscle cells. Differentiated C2C12
indicated. Cell lysates were then collected and the phosphorylation of CREB (fir
tubulin (fourth panel) were also verified.
See also Figure S5.
Results were presented as means ± SEM.
Chemistry & Biology 22, 3Microarray Analysis
Global gene expression in the hindlimb skeletal muscle (a mixture of soleus
and gastrocnemius muscles) and liver tissues was performed using GeneChip
Mouse Gene 1.0 ST Arrays (Affymetrix) as instructed. Results were analyzed
by the computer program GenePattern (Reich et al., 2006).
RT-PCR
Total RNA was prepared by Trizol Isolation Reagent (Invitrogen). First-strand
cDNA from total RNA was synthesized using Superscript III reverse transcrip-
tase (Invitrogen) and oligo-dT17 as primer. Expression of Mup1 (F: CAA AAC
AGA AAA GGC TGG TGA; R: GTT TTA CAA ACT TTT CCT TGA), Plin1
(F: AGA GTT CTG CAG CTG CCT GTG, R: CAG AGG TGC TTG CAA TGG
GCA), Prkar2b (F: CCG TAT GGG CAG ATT GAG TA, R: CTA CTA AAT ACA
AAC AAC AAA AAC CCT), ND6 (F: ATT AAA CAA CCA ACA AAC CCA C,
R: TTT GGT TGG TTG TCT TGG GTT), and b-actin (F: AAC CGT GAA AAG
ATG ACC CAG AT, R: CAC AGC CTG GAT GGC TAC GT) was detected using
RealMasterMix SYBR ROX (5 Prime) on an ABI7500 Real-Time PCR System
(Applied Biosystems). TrkB expression in the brain and muscle of MTKO
mice was examined using TrkB Flox F (ACA CAC ACA GTA TAT TTT ACC A)
and TrkB Flox R (CAA GAA GTC AGA GAC CAG AGA GA). Cre-50 (CCT GGA
AAA TGC TTC TGT CCG TTT GCC); Cre-30 (GAG TTG ATA GCT GGC TGG
TGG CAG ATG).
Fatty Acid Oxidation Assay
Fatty acid oxidation was measured by determining the production of 3H2O
from [9,10-3H]palmitate as reported (Chan et al., 2010). Briefly, albumin-bound
tritiated palmitate was added to C2C12 myotubes and incubated for 2 hr at
37C. After incubation, themediumwas removed and added to a tube contain-
ing cold 10% trichoroacetic acid. The supernatant was then neutralized with
NaOH, applied to ion-exchange resin to separate the 3H2O, and counted by
scintillation counting.
Hyperinsulinemic-Euglycemic Clamp
The hyperinsulinemic-euglycemic clamp was performed at the Vanderbilt
Mouse Metabolic Phenotyping Center. Catheters were implanted into a
carotid artery and a jugular vein of mice for sampling and infusions, respec-
tively, 5 days before the study. Insulin clamps were performed on mice fasted
for 5 hr using a modification of the method described by Ayala et al. (2006).
[3-3H]Glucose was primed (2.4 mCi) and continuously infused for 90-min
equilibration and basal sampling periods (0.04 mCi/min). [3-3H]Glucose was
mixed with the nonradioactive glucose infusate (infusate specific activity of
0.4 mCi/mg) during the 2-hr clamp period. Arterial glucose was clamped usinglls after 7,8-DHF stimulation. Differentiated C2C12 myotubes were stimulated
ed and the phosphorylation of AMPK (first panel) and ACC (third panel) was
.
2 myotubes were stimulated with 7,8-DHF at various concentrations for 24 hr,
VA versus control, n = 3).
erentiated C2C12 myotubes were incubated with TrkB kinase inhibitor K252a
. Cell lysates were then collected and the phosphorylation of AMPK (first panel),
el), ACC (fourth panel), and actin (sixth panel) were also verified.
tiated C2C12 myotubes were transfected with control or myc-TrkB plasmids
osphorylation of AMPK (first panel) and ACC (third panel) was examined. Total
d C2C12myotubes were stimulated with 7,8-DHF at various concentrations for
as thenmeasured (*P < 0.05, **P < 0.01 versus control, one-way ANOVA, n = 3).
2 myotubes were stimulated with 7,8-DHF at various concentrations for 24 hr.
en measured (**P < 0.01, ***P < 0.001 versus control, one-way ANOVA, n = 3).
rentiated C2C12myotubes were incubated with K252a (10 nM) for 1 hr followed
ration of ADP and ATP was then measured (**P < 0.01, ***P < 0.001, two-way
myotubes were stimulated with 7,8-DHF (1 mM) for various time intervals as
st panel) was examined. Total CREB (second panel), UCP1 (third panel), and
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a variable rate of glucose (plus trace [3-3H]glucose) infusion, which was
adjusted based on the measurement of blood glucose at 10-min intervals.
By mixing radioactive glucose with the nonradioactive glucose infused during
a clamp, deviations in arterial glucose-specific activity are minimized and
steady-state conditions are achieved. Baseline blood or plasma variables
were calculated as the mean of values obtained in blood samples collected
at 15 and 5 min. At time zero, insulin infusion (2.5 mU/kg of body weight
per min) was started and continued for 120 min. Mice received heparinized
saline-washed erythrocytes from donors at 5 ml/min to prevent a fall in hemat-
ocrit level. Insulin clamps were validated by assessment of blood glucose over
time. Blood was taken at 80–120 min for the determination of [3-3H]glucose.
Clamp insulin was determined at t = 120 min. At 120 min, 13 mCi of
2[14C]deoxyglucose ([14C]2DG) was administered as an intravenous bolus.
Blood was taken at 2–25 min for the determination of [14C]2DG. After the
last sample, mice were anesthetized and tissues were freeze-clamped for
biochemical analysis. Plasma insulin was determined by ELISA. Radioactivity
of [3-3H]glucose and [14C]2DG in plasma samples and [14C]2DG-6-phosphate
in tissue samples was determined by liquid scintillation counting.
Body Composition Analysis and Indirect Calorimetry
Body composition and indirect calorimetry analyses were performed at the
Vanderbilt Mouse Metabolic Phenotyping Center using Minispec Model
mq7.5 (7.5 mHz) (Bruker Instruments) and the Promethion system (Sable Sys-
tems), respectively. For indirect calorimetry, mice were individually housed for
a week prior to the measurements. Indirect calorimetry was measured for 5
consecutive days. Body composition of mice was assessed before and after
the indirect calorimetry measurement.
ADP/ATP Measurement
Cellular ATP and ADP concentrations were measured using the ApoSENSOR
ADP/ATP Ratio Bioluminescence Assay Kit (BioVision).
In Vitro AMPK Activity
AMPK was immunoprecipitated from lysed HEK293 cells using anti-AMPKa
antibody and Protein A/G agarose (Santa Cruz Biotechnology). The agarose
was then washed extensively with lysis buffer and the kinase activity in phos-
phorylating SAMS peptide was determined as reported (Hardie et al., 2000).
Briefly, immunoprecipitated AMPK was stimulated with 7,8-DHF for 30 min
at 37C. A mixture of [g-32P]ATP, ATP, and SAMS peptide in HEPES buffer
was then added to the immunoprecipitated AMPK and incubated for an addi-
tional 10 min. The reaction mixture was spotted on Whatman paper. After
extensive washing with 1% (v/v) phosphoric acid, the amount of labeled
SAMS peptide was determined by scintillation counting.
Adipogenesis
3T3-L1 cells were grown in DMEMwith 10%CS. Two days after 100% conflu-
ence, the cells were then induced to differentiate into adipocytes by changing
the medium to DMEM containing a standard induction cocktail of 10% fetal
bovine serum (FBS), 0.5 mM 3-isobutyl-1-methylxanthine, 1 mM dexametha-
sone, 1.7 mM insulin, and various concentrations of 7,8-DHF. After 48 hr, this
medium was replaced with DMEM supplemented with 10% FBS, 1.7 mM insu-
lin, 1 mMciglitazone, and various concentrations of 7,8-DHF for 48 hr. The cells
were then further cultured in DMEMwith 10% FBS and various concentrations
of 7,8-DHF until assayed. Lipid accumulation was examined by oil red O stain-
ing, followed by extraction of the absorbed dye using 100% isopropanol and
measurement at 500 nm.
Statistical Analysis
Results were expressed as means ± SEM and were considered significant
when P < 0.05. Statistical analysis of the data was performed using Student’s
t test, one-way or two-way ANOVA followed by Tukey’s multiple comparison
test using the computer program GraphPad Prism (GraphPad Software).
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